Navigation Links
TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights
Date:3/26/2008

31, December 31,

2007 2006

(Unaudited)

Assets

Current assets

Cash and cash equivalents $ 32,500 $ 55,383

Prepaid expenses and other current assets 835 581

Total current assets 33,335 55,964

Long-term assets 5,317 7,471

Total assets $ 38,652 $ 63,435

Liabilities and stockholders' equity

Current liabilities $ 9,036 $ 12,270

Debt and other long-term liabilities 973 4,413

Deferred revenue 2,183 2,183

Total liabilities 12,192 18,866

Total stockholders' equity 26,460 44,569

Total liabilities and stockholders' equity $ 38,652 $ 63,435

TorreyPines Therapeutics, Inc.

Condensed Consolidated Statements of Operations

(in thousands, except share and per share amounts)

Three months ended Twelve months ended

December 31, December 31,

2007 2006 2007 2006

(Unaudited) (Unaudited) (Unaudited)

Revenue $ 2,461 $ 2,461 $ 9,850 $ 9,850

Operating expenses:

Research and development 7,587 4,713 27,977 22,353

General and administrative 1,434 1,985 5,643 3,971

Purchased in-process

research and development - 8,328 - 8,328


'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia
2. TorreyPines Therapeutics to Present at Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference
3. TorreyPines Therapeutics Reports Third Quarter 2007 Results
4. TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
5. TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference
6. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
7. TorreyPines Therapeutics to Present at ThinkEquitys G5 Conference
8. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
9. Amsterdam Molecular Therapeutics to Appoint Alexander Ribbink to Supervisory Board
10. Blake M. Paterson MD, CEO and Co-founder of Alba Therapeutics, Wins Greater Baltimore Committee 2008 Leadership in Bioscience Award
11. Cell Therapeutics, Inc. (CTI) Invest Northwest Presentation to be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... help in the fight against terrorism with the creation ... explosives with the use of light and special glass ... Actuators B: Chemical , the researchers describe a novel ... as low as 6.3 ppm (parts per million). It ... , "Traditionally explosives detection has involved looking for metals ...
(Date:7/10/2014)... Hall effect in bilayer graphene and shown that this ... electric field. , The fractional quantum Hall effect, ... are exposed to large magnetic fields, is a striking ... behave as a single system. However, while the basic ... of this collective behavior remain not well understood, in ...
(Date:7/10/2014)... the University of Illinois at Urbana-Champaign provides new ... of spin and heat at the nanoscale, and ... for data storage and information processing. , ... momentum. In a typical charge current, electrons, spin-angular-momentum ... explained David Cahill, a professor of materials science ...
(Date:1/15/2014)... Automotive, a group of car dealerships headquartered in ... Center and offering free oil change coupons for participation in ... 18 at the Bill Jacobs Cadillac and Chevrolet location from ... )  The Bill Jacobs Auto annual blood ...
Breaking Biology Technology:Detecting trace amounts of explosives with light 2Columbia researchers observe tunable quantum behavior in bilayer graphene 2Columbia researchers observe tunable quantum behavior in bilayer graphene 3University of Illinois study advances limits for ultrafast nano-devices 2Join the Bill Jacobs Auto blood drive and receive a free oil change 2
... , , ... board , Call by over 18% ... Significant funding shortfall identified in the Progen merger proposal , ... , Late last week Progen Pharmaceuticals Limited (ASX: PGL) responded to the ...
... Diffusion Pharmaceuticals LLC, a clinical-stage drug development company ... announced the completion of a $2.9 million private ... overall growth and clinical programs for its lead ... In addition, David G. Kalergis, Chief Executive Officer ...
... BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX ) ... year ended December 31, 2008. Fourth Quarter 2008 Financial ... 2008, the Company reported collaborative and other research and ... for the three months ended December 31, 2007. ...
Cached Biology Technology:Cytopia and Other Progen Shareholders Maintain Call for Meeting 2Cytopia and Other Progen Shareholders Maintain Call for Meeting 3Cytopia and Other Progen Shareholders Maintain Call for Meeting 4Diffusion Pharmaceuticals Announces Completion of a $2.9 Million Private Placement and Company Presentations at Upcoming Industry Conferences in Geneva, Switzerland and Naples, Florida 2Diffusion Pharmaceuticals Announces Completion of a $2.9 Million Private Placement and Company Presentations at Upcoming Industry Conferences in Geneva, Switzerland and Naples, Florida 3BioCryst Reports Fourth Quarter and Year End 2008 Financial Results and Provides Corporate Update 2BioCryst Reports Fourth Quarter and Year End 2008 Financial Results and Provides Corporate Update 3BioCryst Reports Fourth Quarter and Year End 2008 Financial Results and Provides Corporate Update 4BioCryst Reports Fourth Quarter and Year End 2008 Financial Results and Provides Corporate Update 5BioCryst Reports Fourth Quarter and Year End 2008 Financial Results and Provides Corporate Update 6BioCryst Reports Fourth Quarter and Year End 2008 Financial Results and Provides Corporate Update 7BioCryst Reports Fourth Quarter and Year End 2008 Financial Results and Provides Corporate Update 8BioCryst Reports Fourth Quarter and Year End 2008 Financial Results and Provides Corporate Update 9
(Date:7/10/2014)... 2014  Aware, Inc. (NASDAQ: AWRE ), ... announced on June 26, 2014 that its Board of ... per share, or approximately $40 million in total.  The ... and a payment date of July 24, 2014.  The ... set an ex-dividend date for this special cash dividend. ...
(Date:7/10/2014)... , July 2, 2014 It is ... to announce the appointment of the world-renowned Thoracic and ... of Directors. Dr. Ginsburg, with over 34 ... NY Presbyterian Hospital and Good Samaritan Regional Medical Center. ... since the late 1980,s and is considered an expert ...
(Date:7/10/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/h7h8lq/gesture ... "Global Gesture Recognition & Touch-Less Sensing (2D, 3D, ... report to their offering ... & Touch-Less Sensing Market to Grow Exponentially. Touch-less ... but the companies were unable to leverage this ...
Breaking Biology News(10 mins):NASDAQ Sets Ex-Dividend Date for Aware, Inc.'s Special Cash Dividend of $1.75 Per Share 2Avery Biomedical Devices, Inc. announces the appointment of Mark E Ginsburg, M.D. to its Board of Directors 2Global Gesture Recognition & Touch-Less Sensing (2D, 3D, Ultrasonic, IR, Capacitive) Market - Forecasts to 2020 2
... Barbara, Calif.) Coastal marine ecosystems are at risk worldwide ... UC Santa Barbara who have recently published a study in ... performed the first integrated analysis of all coastal areas of ... must address a litany of impacts from human activities, from ...
... publish The HUGO Journal in cooperation with the ... Genomic Medicine, The HUGO Journal has a new ... of HUGO will receive free access to the journal online ... The HUGO Journal will focus on discoveries ...
... PHILADELPHIAThe Academy of Natural Sciences announced today that its ... member of the prestigious Biodiversity Heritage Library. The BHL ... botanical libraries and research institutions worldwide dedicated to digitizing ... it and to make it more widely available. Scanning ...
Cached Biology News:New study ranks 'hotspots' of human impact on coastal areas 2Academy Library accepted to prestigious Biodiversity Heritage Library 2
Mouse monoclonal to Casein Kinase 2 beta ( Abpromise for all tested applications). entrezGeneID: 1460 SwissProtID: P13862...
Alpha-2-antiplasmin precursor (Alpha-2-plasmin inhibitor) (Alpha-2-PI) (Alpha-2-AP). [Source:Uniprot/SWISSPROT;Acc:P08697] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
... monoclonal [HDAC8-48] to HDAC8 Regulation ... several mechanisms such as DNA methylation, ... modifications of histones, which include the ... groups of lysine residues present in ...
Mouse monoclonal antibody raised against a partial recombinant AAAS. NCBI Entrez Gene ID = AAAS...
Biology Products: